TrialNCT03013543Phase 2Completed
Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity
Study sponsor: Rhythm Pharmaceuticals, Inc. · RYTM
Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.
Primary completion2022-03-01Actual
Enrollment · participants213Actual
Source updated2023-08-18Last update listed in the registry record
Version history
Changes to this trial
Pro unlocks the full available history and CSV export. View Pro features
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.